ICT-107 is another vaccine tested for GBM that consists in an autologous dendritic cell pulsed ex vivo with tumor and CSC antigens (AIM-2, HLA-A2, HER2, TRP-2, gp100, and IL13Rα2). Here, IL13RA2 is linked to neoplasm.